RANDOMISED DOUBLE-BLIND PHASE III TRIAL OF CEDIRANIB (AZD 2171) IN RELAPSED PLATINUM SENSITIVE OVARIAN CANCER: RESULTS OF THE ICON6 TRIAL.

被引：0
|
作者：
Raja, F. A. [1 ,2 ]
Perren, T. J. [3 ]
Embleton, A. [4 ]
Rustin, G. J. S. [5 ]
Jayson, G. [6 ]
Swart, A. M. [4 ]
Vaughan, M. [7 ]
Hirte, H. [8 ]
Stark, D. P. [9 ]
Ledermann, J. A. [1 ,2 ]
机构：
[1] Canc Res UK, London, England
[2] UCL Canc Inst, UCL Canc Trials Ctr, London, England
[3] St James Univ Hosp, Dept Oncol, Leeds LS9 7TF, W Yorkshire, England
[4] MRC, Clin Trials Unit, London, England
[5] Mt Vernon Hosp, Dept Oncol, Northwood HA6 2RN, Middx, England
[6] Christie Hosp, Dept Oncol, Manchester, Lancs, England
[7] Christchurch Hosp, Christchurch, New Zealand
[8] Hamilton Reg Canc Ctr, Hamilton, ON L8V 1C3, Canada
[9] St James Univ Hosp, Leeds LS9 7TF, W Yorkshire, England
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2013年 / 23卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial
    Ledermann, J. A.
    Perren, T. J.
    Raja, F. A.
    Embleton, A.
    Rustin, G. J. S.
    Jayson, G.
    Kaye, S. B.
    Swart, A. M.
    Vaughan, M.
    Hirte, H.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S5 - S6
  • [2] Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial
    Ledermann, Jonathan A.
    Embleton, Andrew C.
    Raja, Fharat
    Perren, Timothy J.
    Jayson, Gordon C.
    Rustin, Gordon J. S.
    Kaye, Stan B.
    Hirte, Hal
    Eisenhauer, Elizabeth
    Vaughan, Michelle
    Friedlander, Michael
    Gonzalez-Martin, Antonio
    Stark, Daniel
    Clark, Elizabeth
    Farrelly, Laura
    Swart, Ann Marie
    Cook, Adrian
    Kaplan, Richard S.
    Parmar, Mahesh K. B.
    LANCET, 2016, 387 (10023): : 1066 - 1074
  • [3] Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial
    Ledermann, J. A.
    Embleton-Thirsk, A. C.
    Perren, T. J.
    Jayson, G. C.
    Rustin, G. J. S.
    Kaye, S. B.
    Hirte, H.
    Oza, A.
    Vaughan, M.
    Friedlander, M.
    Gonzalez-Martin, A.
    Deane, E.
    Popoola, B.
    Farrelly, L.
    Swart, A. M.
    Kaplan, R. S.
    Parmar, M. K. B.
    ESMO OPEN, 2021, 6 (02)
  • [4] Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer
    Raja, F. A.
    Griffin, C. L.
    Qian, W.
    Hirte, H.
    Parmar, M. K.
    Swart, A. M.
    Ledermann, J. A.
    BRITISH JOURNAL OF CANCER, 2011, 105 (07) : 884 - 889
  • [5] Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer
    F A Raja
    C L Griffin
    W Qian
    H Hirte
    M K Parmar
    A M Swart
    J A Ledermann
    British Journal of Cancer, 2011, 105 : 884 - 889
  • [6] Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer
    Ledermann, Jonathan A.
    Embleton, Andrew C.
    Perren, Timothy
    Jayson, Gordon C.
    Rustin, Gordon J. S.
    Kaye, Stanley B.
    Hirte, Hal W.
    Oza, Amit M.
    Vaughan, Michelle Margaret
    Friedlander, Michael
    Martin, Antonio Gonzalez
    Clark, Elizabeth
    Popoola, Babasola
    Farrelly, Laura
    Swart, Ann Marie
    Cook, Adrian
    Kaplan, Richard S.
    Parmar, Mahesh K. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Quality of Life With Cediranib in Relapsed Ovarian Cancer: The ICON6 Phase 3 Randomized Clinical Trial
    Stark, Dan P.
    Cook, Adrian
    Brown, Julia M.
    Brundage, Michael D.
    Embleton, Andrew C.
    Kaplan, Richard S.
    Raja, Fharat A.
    Swart, Ann Marie W.
    Velikova, Galina
    Qian, Wendi
    Ledermann, Jonathan A.
    CANCER, 2017, 123 (14) : 2752 - 2761
  • [8] Fuzuloparib maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer: a multicenter, randomized, double-blind, placebo-controlled, phase III trial
    Li, Ning
    Zhang, Youzhong
    Wang, Jing
    Zhu, Jianqing
    Wang, Li
    Wu, Xiaohua
    Yao, Desheng
    Wu, Qiang
    Liu, Jihong
    Tang, Junying
    Yin, Rutie
    Zhang, Guonan
    Lou, Ge
    An, Ruifang
    Xia, Xiaoping
    Li, Qingshui
    Zhu, Yaping
    Hong, Zheng
    Yang, Xinfeng
    Hu, Yuanjing
    Zhang, Xin
    Wan, Xiaoyun
    Qu, Jing
    Zhang, Ben
    Wu, Lingying
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S57 - S58
  • [9] HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY IN PLATINUM-SENSITIVE RELAPSED EPITHELIAL OVARIAN CANCER: THE CHIPOR RANDOMISED PHASE III TRIAL
    Classe, Jean-Marc
    Meeus, Pierre
    Leblanc, Eric
    Wernert, Romuald
    Quenet, Francois
    Marchal, Frederic
    Houvenaeghel, Gilles
    Bats, Anne-Sophie
    Lecuru, Fabrice
    Ferron, Gwenael
    Brigand, Cecile
    Berton, Dominique
    Gladieff, Laurence
    Joly, Florence
    Coquard, Isabelle Ray
    Durand-Fontanier, Sylvaine
    Brument, Emilie
    Asselain, Bernard
    Campion, Loic
    Glehen, Olivier
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A29 - A29
  • [10] A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca)
    Liu, Joyce F.
    Barry, William Thomas
    Wenham, Robert Michael
    Hendrickson, Andrea Elisabeth Wahner
    Armstrong, Deborah Kay
    Chan, Nancy
    Cohn, David E.
    Lee, Jung-Min
    Penson, Richard T.
    Cristea, Mihaela C.
    Abbruzzese, James L.
    Matsuo, Koji
    Olawaiye, Alexander
    Farooq, Sarah
    Swisher, Elizabeth M.
    Van Allen, Eliezer Mendel
    Shapiro, Geoffrey
    Kohn, Elise C.
    Ivy, S. Percy
    Matulonis, Ursula A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345